权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Overcoming Resistance in HER2-positive Breast Cancer

克服 HER2 阳性乳腺癌的耐药性

基本信息

批准号：
9987996
负责人：
Elizabeth S. Yeh
金额：
$ 33.58万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9987996
关键词：
Address Adult Apoptosis Apoptotic Applications Grants Autophagocytosis BCL2 gene BT 474 Breast Cancer Cell Breast Cancer Model Breast Cancer Treatment Breast Cancer cell line CASP3 gene Catabolic Process Cell Death Cell Survival Cells Cessation of life Cleaved cell Combined Modality Therapy Data Data Analyses Dose Down-Regulation Drug Screening ERBB2 gene Exhibits Gene Expression Genetic Goals Growth HER2 inhibition Hormonal Human Impairment In Vitro Incidence Intervention JNK-activating protein kinase KRP protein Knock-out MAPK8 gene Mammary gland Mediating Methods Modeling Molecular Mus Neoplasm Metastasis Pathway interactions Pharmacology Phosphotransferases Prevention approach Process Protein Kinase Proteins Publishing Refractory Research Resistance Reverse Transcriptase Polymerase Chain Reaction Role Route Sampling Signal Pathway Signal Transduction Stains Stress Testing Therapeutic Intervention Trastuzumab Work Xenograft procedure base cell transformation combat improved in vivo in vivo Model inhibitor/antagonist innovation knock-down lapatinib mRNA Expression malignant breast neoplasm mutant neoplastic cell novel novel therapeutics prevent public health relevance response small hairpin RNA targeted treatment therapy resistant tumor tumor growth tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Overcoming resistance is a central challenge to finding a cure for breast cancer. A number of mechanisms have been suggested for how breast cancer cells escape treatment and survive, indicating potential novel avenues for therapeutic intervention. These mechanisms include the ability of breast cancer cells to turn on pathways to evade apoptotic cell death and to use the catabolic process, autophagy, as a survival mechanism. We have characterized a novel AMPK-related protein kinase, Hunk, to be critical for breast cancer growth and progression by virtue of its ability to mediate tumor cell survival, and provide evidence that Hunk regulates apoptosis and autophagy. Hunk is upregulated by HER2/neu to promote tumorigenesis, and suppresses apoptosis while promoting autophagy in response to stress such as HER2 inhibitor treatment, indicating that targeting Hunk will combat resistance to HER2 inhibition by blocking these escape pathways. The long-term goal of this research is to identify methods to improve breast cancer treatment by overcoming or evading resistance. The overall objective of this proposal is to demonstrate the molecular mechanisms by which Hunk kinase regulates apoptosis and autophagy to delineate Hunk's role in mediating resistance to breast cancer treatment. The rationale for the proposed research is that, once it is understood the mechanism by which Hunk regulates cell survival and how this impacts breast cancer treatment, the activity of this kinase could be manipulated pharmacologically, resulting in a new and innovative approach for the prevention and treatment of resistance in breast cancers. To pursue this rationale, we hypothesize that Hunk facilitates resistance to HER2 inhibition by regulating two cell death pathways: apoptosis and autophagy. Therefore, inhibiting Hunk will overcome resistance by blocking these escape mechanisms. To test this hypothesis, the following specific aims are proposed. Aim 1: Determine the mechanisms by which Hunk regulates cell survival to mediate resistance to HER2 inhibitors by assessing (A) whether Hunk signals through intrinsic or extrinsic apoptotic pathways and canonical or non-canonical routes of autophagy as well as whether Hunk regulates crosstalk between these pathways. (B) Determine if Hunk facilitates resistance in an Akt-dependent manner. Aim 2: To demonstrate that (A) targeting Hunk impairs tumorigenesis in trastuzumab and lapatinib resistant BrCa and (B) evaluate JNK signaling in promoting resistance because we find that targeting JNK is effective in killing resistant breast cancer cells and collaborates with Hunk targeting. The contribution of the proposed research is expected to be the elucidation of novel molecular activities of Hunk that regulate cell survival mechanisms, apoptosis and autophagy, which cause breast cancers to become resistant to treatment. These contributions are significant and conceptually innovative because they provide novel avenues for pharmacologic intervention in preventing and/or overcoming resistance to breast cancer treatment.